However, dual-acting H3R/H4R ligands may also present therapeutic potential in determined pathological conditions, such as neuropathic pain (Smith et al., 2007), cancer (Medina et al., 2008), and have also been reported in Parkinson’s disease (Shan et al., 2015a,b). Here, HRH4 is linked to cancer.